Type: Product
Name: Gleevec
First reported Oct 28 2014 - Updated Oct 28 2014 - 3 reports

Novartis’ strong third-qtr boosted by sale of Idenix stake

Swiss pharma major Novartis (NOVN: VX) this morning reported that sales for the third quarter of 2014 rose 4% to $14.7 billion, beating analysts’ forecast of $14.55 billion, boosted by strong sales of new products such as Gilenya (fingolimod) for multiple ... [Published Pharma Letter - Oct 28 2014]
First reported Oct 28 2014 - Updated Oct 28 2014 - 1 reports

Pharma Patents in India

These points are from a talk given by Pravin Anand at fieldfisher’s Pharma Patents Seminar on 16 October 2014.1. There is an anti-patents environment in India where patent protection is provided due to the compulsion of TRIPS rather than to advance innovation. ... [Published Connect - Oct 28 2014]
First reported Oct 28 2014 - Updated Oct 28 2014 - 1 reports

Novartis third-quarter profit beats estimates on sale of Idenix stake

Swiss drugmaker Novartis reported better-than-expected results on Tuesday, as a pre-tax gain from the sale of its shareholding in Idenix offset full copycat competition to its former best-selling blood pressure pill Diovan.The Basel-based firm reported ... [Published 4 Traders - Oct 28 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

Novartis Drags DRL to Court over Gleevec

HYDERABAD:  Basel-headquartered Novartis Pharmaceuticals Corporation and Novartis AG dragged city-based Dr Reddy's Laboratories Ltd (DRL) and its US subsidiary Dr Reddy's Laboratories Inc to the US court over alleged patent infringement.As per Novartis' ... [Published New Indian Express - Oct 21 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

Achtung! Patents Ahead

For almost 10 years now, 12 countries, led by the United States, have been negotiating a behind-closed-doors, wide-ranging, multi-nation trade agreement known as the Trans-Pacific Partnership (TPP). The Trans-Pacific Partnership covers a vast spectrum ... [Published Outlook India - Oct 21 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 5 reports

NICE swayed by long term Glivec data

NICE has reversed a long-standing block on using Glivec in GIST tumours, saying new evidence has persuaded it to change its mind.Final draft guidance published today proposes to recommend Novartis' Glivec (imatinib) for up to three years for peo...Related ... [Published BioPortfolio - Oct 17 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Access to good therapy is big issue for patients in poorer nations

Pharma companies will have to change their approach if the demand for affordable cancer drugs in poor countries is to be met.(Keystone)When Dr Mohga Kamal-Yanni spent a month in her native Egypt over the summer, she was struck by both the rising demand ... [Published Swiss Info - Oct 14 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

Chemotherapy is brutal, but targeted drugs can reduce collateral damage

By using a targeted drug doctors can reduce the dosage of chemotherapy, improving patients’ quality of life. Photograph: Christopher Thomond/GuardianWhen I first studied cancer medicine as an undergraduate, my lecturer described chemotherapy as “beating ... [Published - Oct 09 2014]
First reported Oct 06 2014 - Updated Oct 07 2014 - 1 reports

60 Minutes Just Attacked High Drug Prices. Here's What You Should Know

60 Minutes , the most successful news program in American history, just took aim at the extraordinarily high ($100,000 per patient per year) prices charged for cancer drugs. The pharmaceutical industry, which only provided canned statements and badly ... [Published - Oct 06 2014]
First reported Oct 06 2014 - Updated Oct 06 2014 - 1 reports

Nat’l oncologists group tackles spiraling drug costs

Dr. Richard Schilsky of the American Society of Clinical Oncology discusses the high price of Gleevec, a leukemia wonder drug. ... [Published CBS News - Oct 06 2014]
First reported Oct 03 2014 - Updated Oct 03 2014 - 1 reports

United in cause, spirit

Carrying the Relay For Life banner along with friend Sheila Martin (not pictured) Friday Harbor’s Ruthe Ramirez leads the “Survivor’s Walk” procession at the annual fundraiser.— image credit: Journal photo / Scott RasmussenBreakthroughs come along every ... [Published - Oct 03 2014]
First reported Oct 02 2014 - Updated Oct 02 2014 - 1 reports

Pharmaceutical companies refute Congress' post claiming hike in prices of life-saving drugs

B y Divya RajagopalMUMBAI: A post on the Congress party's website claiming steep hikes in the prices of life-saving medicines, especially cancer drug Glivec, has led to the social media playing it up and also creating confusion.Novartis, which owns the ... [Published Economic Times - Oct 02 2014]


"Novartis has been granted these patents since 2008-09 but has chosen not to manufacture the same in India. Novartis merely imports a negligible quantity of these products manufactured in Switzerland as per its own data filed before the Patent office" Cipla said in a statement (as quoted by The Economic Times)
"Cipla believes that it has the potential to manufacture adequate quantities of the drug and make the same available in the country" the company said in a statement
Joseph Jimenez, chief executive of Novartis, said: "Novartis delivered a very strong third quarter. We delivered solid sales growth with margin expansion. At the same time, we reached key innovation milestones, particularly with LCZ696 in heart failure and AIN457 in psoriasis, underlining the innovation power of the company.”"

More Content

All (136) | News (117) | Reports (0) | Blogs (19) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Cipla petitions India to revoke Novartis respir... [Published FiercePharma - 14 hours ago]
Cipla wants Novartis's patents on respiratory d... [Published domain-b - Oct 30 2014]
Cipla asks India to revoke Novartis patents on ... [Published Sharenet - Oct 30 2014]
Novartis’ strong third-qtr boosted by sale of I... [Published Pharma Letter - Oct 28 2014]
Pharma Patents in India [Published Connect - Oct 28 2014]
Novartis' (NVS) CEO Joe Jimenez on Q3 2014 Resu... [Published Seeking Alpha - Oct 28 2014]
Novartis results top forecasts as new products ... [Published Yahoo! Finance UK and Ireland - Oct 28 2014]
Novartis results top forecasts as new products ... [Published Mail Online UK - Oct 28 2014]
Novartis third-quarter profit beats estimates o... [Published 4 Traders - Oct 28 2014]
Novartis Third-Quarter Profit Climbs on New Pro... [Published Bloomberg - Oct 28 2014]
Under US pressure, Indian government is getting... [Published Pharma Letter - Oct 27 2014]
Will Novartis (NVS) Disappoint in Q3 Earnings S... [Published - Oct 27 2014]
Capitulation on IP: Reaching a Point of no Return? [Published Peoples - Oct 22 2014]
The battle against Big Pharma for cheap drugs [Published - Oct 22 2014]
Novartis Drags DRL to Court over Gleevec [Published New Indian Express - Oct 21 2014]
Achtung! Patents Ahead [Published Outlook India - Oct 21 2014]
Court Report - October 2014 #3 [Published JD Supra - Oct 20 2014]
USTR’s Investigations On IP Rights Against Indi... [Published Intellectual Property Watch - Oct 20 2014]
NICE swayed by long term Glivec data [Published BioPortfolio - Oct 17 2014]
NICE reviews guidance on imatinib for digestive... [Published NICE - Oct 17 2014]
NICE reverses guidance on Novartis’ Glivec for ... [Published Pharma Letter - Oct 17 2014]
Novartis cancer drug beating path to NHS [Published BioPortfolio - Oct 17 2014]
Novartis cancer drug beating path to NHS [Published Pharmafocus - Oct 17 2014]
NICE backs Novartis' Glivec for GIST [Published Pharma Times - Oct 17 2014]
Lab-Made Blood Cells Hunt Cancer, Leading to Re... [Published The Verge - Oct 15 2014]
Big Pharma Cashes in on Americans Paying (Highe... [Published Drug Watch - Oct 15 2014]
ARIAD's Iclusig Gains Positive Recommendation f... [Published - Oct 14 2014]
Top 10 Most Expensive Drugs of 2013 [Published P&T Community - Oct 14 2014]
US launches review of India's Intellectual Prop... [Published Economic Times - Oct 14 2014]
Access to good therapy is big issue for patient... [Published Swiss Info - Oct 14 2014]
1 2 3 4 5
In Focus
Content Volume
Document Volume


sort by: Date | Relevance
'60 Minutes' Delivers Blow to Big Pharma over D... [Published - Oct 06 2014]
60 Minutes has just produced a piece on drug pricing that is a must watch for anyone in the industry. The details of the story are somewhat old.  60 Minutes has caught up with two doctors who in 2012 told drug makers, “enough.”   In October of 2012, ...
Novartis fails to report side effects, fatality [Published PharmaGossip - Aug 30 2014]
6:52 pm, August 30, 2014 Jiji PressNovartis Pharma K.K. said it has failed to report to the health ministry at least 2,579 cases of serious side effects, including a fatality, from its drugs for leukemia and other diseases even though its employees ...
Improving the FDA, Ctd [Published The Daily Dish | By Andrew Sullivan - Aug 16 2014]
by Elizabeth Nolan Brown Should the U.S. Food and Drug Administration inch closer to Europe’s drug approval model , in which certified, independent bodies can (and compete to) review new products? A Dish reader says, hey, it worked for the Federal ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 05 2014]
Phenotypic Assays in Cancer Drug Discovery [Published In the Pipeline - Jul 24 2014]
The topic of phenotypic screening has come up around here many times, as indeed it comes up very often in drug discovery. Give your compounds to cells or to animals and look for the effect you want: what could be simpler? Well, a lot of things could, ...
1 2 3 4
Contact Us

Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.